NCT04212598View on ClinicalTrials.gov

The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 3, 2020

Primary Completion Date

November 3, 2024

Study Completion Date

November 4, 2024

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Sintilimab

Patients who completed concurrent chemoradiotherapy standard dose would received the Sintilimab as a consolidate therapy for one year.

Trial Locations (1)

430071

Zhongnan Hospital of Wuhan University, Wuhan

All Listed Sponsors
lead

Wuhan University

OTHER

NCT04212598 - The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer | Biotech Hunter | Biotech Hunter